Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert® MTB/RIF in Zimbabwe

Public Health Action

Volumn 6, Issue 2, 2016, Pages 122-128

  Charambira, Kelvin ^a   Ade, S ^b,c   Harries, A D ^b,d   Ncube, R T ^a   Zishiri, C ^a   Sandy, C ^e   Mutunzi, H ^e   Takarinda, K ^b,e   Owiti, P ^b   Mafaune, P ^e   Chonzi, P ^f  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (Zimbabwe)

^b The Union   (France)

^c National Programme for Tuberculosis and Pulmonary Diseases   (Benin)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e MINISTRY OF HEALTH AND CHILD CARE   (Zimbabwe)

^f Harare City Health Department   (Zimbabwe)

Author keywords

Culture and drug susceptibility testing; MDR TB; RMP resistance; SORT IT; Tuberculosis; Xpert MTB RIF

Indexed keywords

RIFAMPICIN;

ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; COHORT ANALYSIS; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; RAPID TEST; RETROSPECTIVE STUDY; TIME TO TREATMENT; TUBERCULOSIS; ZIMBABWE;

EID: 85043403932     PISSN: None     EISSN: 22208372     Source Type: Journal    
DOI: 10.5588/pha.16.0005     Document Type: Article

References (30)

1. World Health Organization. Global tuberculosis report 2014. WHO/HTM/ TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. Zimbabwe Ministry of Health and Child Care. Zimbabwe National and Sub-National HIV and AIDS Estimates 2014. Harare, Zimbabwe: Ministry of Health and Child Care, 2014.
3. Reid M J A, Shah N S. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9: 173-184.
4. Lawn S D, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011; 204 (Suppl 4): S1159-S1167.
5. Harries A D, Zachariah R, Corbett E L, et al. The HIV-associated tuberculosis epidemic—when will we act? Lancet 2010; 375: 1906-1919.
6. Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
7. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
8. World Health Organization. Policy statement: automated realtime nucleic acid amplification technology for rapid and simultaneous detection of tu-berculosis and rifampicin resistance: Xpert MTB/RIF system. WHO/HTM/ TB/2011.4. Geneva, Switzerland: WHO, 2011.
9. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational ‘how-to’. Practical considerations. WHO/HTM/TB/2011. Geneva, Switzerland: WHO, 2011.
10. World Health Organization. Xpert MTB/RIF assay for diagnosis of pulmonary and extra-pulmonary TB in adults and children. 2013. Policy update. WHO/HTM/TB/2013.16. Geneva, Switzerland: WHO, 2013.
11. Botha E, Den Boon S, Verver S, et al. Initial default from tuberculosis treatment: how often does it happen and what are the reasons? Int J Tuberc Lung Dis 2008; 12: 820-823.
12. Afutu F K, Zachariah R, Hinderaker S G, et al. High initial default in patients with smear-positive pulmonary tuberculosis at a regional hospital in Accra, Ghana. Trans R Soc Trop Med Hyg 2012; 106: 511-513.
13. Harries A D, Rusen I D, Chiang C-Y, Hinderaker S G, Enarson D A. Registering initial defaulters and reporting on their treatment outcomes. Int J Tuberc Lung Dis 2009; 13: 801-803.
14. World Health Organization. WHO End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, Switzerland: WHO, 2015. http://www.who.int/tb/post2015_strategy/en/ Accesssed February 2016
15. The World Bank. Working for a world free of poverty. Washington, DC, USA: World Bank, 2015. http://data.worldbank.org/country/zimbabwe Accessed February 2016
16. Zimbabwe National Statistics Agency. Census 2012. Preliminary Report. Harare, Zimbabwe: National Statistics Agency, 2012.
17. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug resistant tuberculosis. WHO/ HTM/TB.2014.11. Geneva, Switzerland: WHO, 2014.
18. von Elm E, Altman D G, Egger M. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007; 85: 867-872.
19. Sikhondze W, Dlamini T, Khumalo D, et al. Countrywide roll-out of Xpert® MTB/RIF in Swaziland: the first three years of implementation. Public Health Action 2015; 5: 140-146.
20. Harries A D, Michongwe J, Nyirenda T E, et al. Using a bus service for transporting sputum specimens to the Central Reference Laboratory: effect on the routine TB culture service in Malawi. Int J Tuberc Lung Dis 2004; 8: 204-210.
21. Kilale A M, Ngowi B J, Mfinanga G S, et al. Are sputum samples of retreatment tuberculosis reaching the reference laboratories? A 9-year audit in Tanzania. Public Health Action 2013; 3: 156-159.
22. Chadha S S, Sharath B N, Reddy K, et al. Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLOS ONE 2011; 6: e26659.
23. Qi W, Harries A D, Hinderaker S G. Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China. Int J Tuberc Lung Dis 2011; 15: 137-139.
24. Tharu M B, Harries A D, Goel S, et al. Screening retreatment tuberculosis patients for drug resistance in mid-west Nepal: how well are we doing? Public Health Action 2014; 4: 60-65.
25. van Kampen S C, Tursynbayeva A, Koptleuova A, et al. Effect of introducing Xpert MTB/RIF to test and treat individuals at risk of multidrug-resistant tuberculosis in Kazakhstan: a prospective cohort study. PLOS ONE 2015; 10: e0132514.
26. World Health Organization. Global tuberculosis report 2015. WHO/HTM/ TB/2015.22. Geneva, Switzerland: WHO, 2015.
27. Rifat M, Hall J, Oldmeadow C, Husain A, Milton A H. Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh. BMC Infect Dis 2015; 15: 526.
28. Takarinda K C, Harries A D, Nyathi B, Ngwenya M, Mutasa-Apollo T, Sandy C. Tuberculosis treatment delays and associated factors within the Zimbabwe national tuberculosis programme. BMC Public Health 2015; 15: 29.
29. Naidoo P, van Niekerk M, du Toit E, et al. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients’ experiences in the era of rapid molecular diagnostic tests. BMC Health Services Research 2015; 15: 488.
30. United Nations. Transforming our world: the 2030 agenda for sustainable development. New York, NY, USA: United Nations, 2015. http://sustainabledevelopment.un.org/post2015/transformingourworld Accessed February 2016